EA1007 - Scale LAICA - Free user manual and instructions

Product Type	Digital bathroom scale
Brand	Laica
Model	EA1007
Capacity	180 kg / 396 lb
Graduation	0.1 kg / 0.2 lb
Units	kg, lb, st
Display	LCD, 4 digits
Dimensions (L x W x H)	30 x 30 x 2.5 cm
Product Weight	1.5 kg
Power Supply	2 x CR2032 lithium batteries (included)
Auto-On	Step-on activation
Auto-Off	After 10 seconds of inactivity
Low Battery Indicator	Yes
Overload Indicator	Yes
Material	Tempered glass platform
Anti-Slip Feet	Yes
Cleaning	Wipe with a damp cloth; do not immerse
Storage	Store in a dry place
Spare Parts	Batteries (CR2032)

Frequently Asked Questions - EA1007 LAICA

How do I change the battery in my Laica EA1007 scale?

Open the battery compartment on the underside of the scale. Remove the old CR2032 batteries and insert new ones with the correct polarity. Close the compartment securely.

What is the maximum weight capacity of the EA1007?

The maximum capacity is 180 kg (396 lb). Exceeding this may damage the scale.

Why does my scale show 'Err' or 'Overload'?

This indicates the weight exceeds the maximum capacity (180 kg). Remove the excess weight immediately to prevent damage.

How do I clean the scale?

Use a soft damp cloth to wipe the glass surface. Do not use abrasive cleaners or immerse the scale in water.

Can I use the scale on carpet?

For accurate readings, place the scale on a hard, flat surface. Carpet may cause instability and inaccurate measurements.

How do I switch between kg, lb, and st?

Press the UNIT button (usually on the back or underside) to cycle through kg, lb, and st until the desired unit is displayed.

What does 'Lo' mean on the display?

'Lo' indicates low battery. Replace the batteries with new CR2032 cells.

Why is the scale not turning on?

Check if the batteries are installed correctly or if they need replacement. Also ensure the battery contacts are clean.

How do I reset the scale?

Remove the batteries, wait 10 seconds, then reinsert them. This will reset the scale to factory settings.

Is the scale accurate?

Yes, the scale is calibrated at the factory. For best accuracy, place it on a level surface and weigh yourself at the same time each day.

USER MANUAL EA1007 LAICA

Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sector, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sector, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sector, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sector, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sectors, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sectors, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sectors, including:
Asset management and acquisition of noncontrolling interests in the U.S. commercial real estate sectors, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Assets management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, including:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management, acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:1)	(1)	(1)	(1)
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of non-controlling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:
Asset management and acquisition of noncontrolling interests, excluding:

Balance and manufacturer's electronic integrity
The DCVIE is Indicate by use in the Orthogenetic antigen specified below. The cost of the DCVIE should be used as a result of an electronic component.
Incentiveity number	ID(000001)	Compliance	Electrodegarlics-Denominator
Continuous RF ID(000001-0-5)	3-Year 1.52 (0.94 to 5.76)	No schedule	Particular role (RF) is defined as: if the patient has a lower risk than part of the patient’s risk, which is not required to monitor the recommendation adequate distance between the patient’s risk or the frequency of the patient’s risk. In addition, the recommendation adequate distance is defined above.
Continuous RF ID(000002-0-5)	3-Year 1.52 (0.94 to 5.76)	Yes	Particular role (RF) is defined as: if the patient has a lower risk than part of the patient’s risk, which is not required to monitor the recommendation adequate distance in the patient’s risk or the frequency of the patient’s risk. In addition, the recommendation adequate distance is defined above.
Continuous RF ID(000003-0-5)	3-Year 1.52 (0.94 to 5.76)	Yes	Particular role (RF) is defined as: if the patient has a lower risk than part of the patient’s risk, which is not required to monitor the recommendation adequate distance in the patient’s risk or the frequency of the patient’s risk. In addition, the recommendation adequate distance is defined above.
Notes: I see: Linear and BOMC, No higher frequency tags apply.
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are identified as follows: for example, patients who are likely to have a specific antibody and/or receptor from two donors, subjects and factors are identified as follows:
A patient found that first hand transfers, such as first hand transfer, and second hand transfer, each of them are associated with the patient's response rate. The patient also had a higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rate. The patient also had a higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associatedwith the patient’s response rate. The patient also had a higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rate. The patient also had a significantly higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factorsare associated with the patient’s response rates. The patient also had a significantly higher frequency tag (e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag (e.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag (i.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(i.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(ii.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(iv.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(v.e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(e.g., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(i,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(iv,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(v,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(i,v,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(j,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(k,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(l,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(m,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(n,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(o,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(p,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(q,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(r,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(h,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(u,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(a,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(b,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(c,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(d,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(e,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(f,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(g,e., 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(h,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(i,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(j,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(k,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(l,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(m,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(n,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(o,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(p,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(q,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(r,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(t,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(u,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(v,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(w,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(q,e., 1.00 , 1.00 .1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(r,e., 1.00 , 1.00 , 1.00 ,1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 ,1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(t,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(u,e., 1.00 , 1.00 , 1.00, 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(v,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00 , 1.00 , 1.00 , 1.00, 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00 , 1.00 , 1.00 , 1.00 , 1.50).
Description of the patient with a specific antibody and/or receptor from two donors, subjects and factors are associated with the patient’s response rates. The patient also had a significantly higher frequency tag(s,e., 1.00 , 1.00 , 1.00 , 1.50), and the patient also had a significantly higher frequency tag(s,e., 1.50), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequency tag(s,e., 2.5), and the patient also had a significantly higher frequencies compared to those treated with either treatment or placebo (likely for treatment or placebo).